Julie Gralow, Chief Medical Officer at American Society of Clinical Oncology (ASCO), shared on LinkedIn:
“Over the past few years, I’ve had the privilege of standing alongside ASCO members from across the U.S. as we’ve met with policymakers to share why federal cancer research funding matters. And while every oncologist and researcher brings a unique perspective, I’ve been struck by how often three key themes come up:
- Cancer breakthroughs don’t happen overnight. They’re built over decades of research.
- Scientific progress depends on steady support for cancer researchers. Without stable funding, we risk losing the pipeline of talented researchers and clinicians who hold the keys to unlocking future cancer breakthroughs.
- Every investment in cancer research is an investment in patients. More treatment options, more time, and more hope.
The progress we’ve made against cancer wasn’t inevitable. It was made possible by decades of commitment to research. The breakthroughs of tomorrow will depend on the choices we make today and that’s why I’m proud to join my ASCO colleagues in advocating for robust, sustained funding for the NIH and NCI. Join us and make your voice heard.”
Save Research. Stop Cancer – ASCO.
You can also read:
Cancer Research Funding: Underfunded or Unequally Distributed?
